Skip to content

Use of low-dose esketamine in anesthesia induction in elderly hypertensive patients

Use of low-dose esketamine in anesthesia induction in elderly hypertensive patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086838
Enrollment
Unknown
Registered
2024-07-11
Start date
2023-12-05
Completion date
Unknown
Last updated
2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Experimental group:Use of low-dose esketamine (0.2 mg/kg intravenously) for anesthesia induction
Control group:Anesthesia induction without the use of low-dose esketamine (use the same volume of normal saline as the experimental group)

Sponsors

Guangdong Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 65-80 with a history of hypertension and good control who are going to undergo tracheal intubation and general anesthesia surgery, regardless of gender; 2.The ASA level is II to III; 18kg/m^2=BMI=28kg/m^2; 3.Those who have good cognitive function during the screening period and can communicate and cooperate normally; 4.Those who voluntarily sign the informed consent form; 5.Those who plan to remove the endotracheal tube and return to the ward after the operation.

Exclusion criteria

Exclusion criteria: 1.Patients with poorly controlled or untreated hypertension (SBP>180mmHg or DBP>110mmHg), congestive heart failure, severe cardiac arrhythmia, unstable angina, recent (within 6 months) myocardial infarction, or cerebrovascular events. 2.Patients with severe obesity (BMI >40), Modified Mallampati Score 4, or known to have a severely difficult airway. 3.Patients with a history of previous neurological diseases such as epilepsy, Parkinson's, etc., severe impairment of consciousness, or psychiatric diseases such as major depression, schizophrenia, bipolar abnormalities, mental confusion, etc; 4.Patients with severe hepatic insufficiency or decompensation (Child-Pugh classification of grade C), severe renal insufficiency, or uremia (greater than CKD4 stage); 5.Those with a history of analgesic and alcohol abuse in the past; 6.Those who are allergic to the drugs used in this study.

Design outcomes

Primary

MeasureTime frame
Difference in mean arterial pressure;

Secondary

MeasureTime frame
Plasma catecholamines;Plasma cortisol;Postoperative adverse events;Postoperative recovery quality;Hemodynamic parameters at T0-T5;

Countries

China

Contacts

Public ContactSun Yi

Guangdong Provincial People's Hospital

591978939@qq.com+86 139 2885 2316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026